乐
乐观
乐观 · 25%PLRZ
$0.90
情景价格
$11.045
-0.519 (-4.70%)收盘时
Loading chart…
- 最高
- 11.590
- 开盘
- 11.590
- 成交量加权均价
- 11.21
- 成交量
- 7.75K
- 市值
- —
- 最低
- 11.000
- 成交额
- 86.85K
- 企业价值/息税折旧摊销前利润（TTM）
- 0.00
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers..
AI 分析 of Polyrizon Ltd (PLRZ)
买入Polyrizon Ltd. is a good buy right now due to its recent clinical trial initiation for NASARIX, which targets seasonal allergic rhinitis, and a strong 1-year price increase of 110.72%. The current price of $11.05 is significantly below its 52-week high of $18.20, indicating potential for growth. However, the company has reported significant losses, with a net income of -3,158,000 USD in Q4 2025, which presents a risk.
估值指标
Polyrizon Ltd（PLRZ）当前预期市盈率为 0.00，5 年平均预期市盈率为 0.00。
Alphio AI 对 PLRZ 的价格情景
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重（25 / 50 / 25），不构成保证。
事件时间线
资讯
9.010-27NewsfilterPolyrizon Completes Patient Enrollment for NASARIX Clinical Study
9.009-22NASDAQ.COMPolyrizon Initiates Clinical Trial for Seasonal Allergic Rhinitis Treatment
- 8.509-04Newsfilter
Polyrizon Closes $4 Million Financing Round
8.509-03NASDAQ.COMPolyrizon Secures $4 Million Financing Through Direct Offering and Private Placement
- 8.509-02Newsfilter
Polyrizon Completes Clinical Site Contracts for NASARIX™ Study
PLRZ 常见问题 —— 由 Alphio AI 解答
Polyrizon Ltd is an Israel-based biotechnology company. The Company is primarily engaged and specializing in the development of medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Its naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a biological mask with a thin shield containment barrier in the nasal cavity. The Company is focused not only on the development of intranasal products, but also on commercialization. The Company cooperates with medical specialists and researchers.. It operates in the Healthcare sector.
Polyrizon Ltd. is a good buy right now due to its recent clinical trial initiation for NASARIX, which targets seasonal allergic rhinitis, and a strong 1-year price increase of 110.72%. The current price of $11.05 is significantly below its 52-week high of $18.20, indicating potential for growth. However, the company has reported significant losses, with a net income of -3,158,000 USD in Q4 2025, which presents a risk.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。